Highlights Mereo BioPharma Group plc

Equities

MREO

US5894921072

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
3.03 ^USD	-7.34%		-7.06%	+31.17%

05-10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT
05-03	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	05-10	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	05-03	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	05-01	MT
European Equities Traded in the US as American Depositary Receipts Decline	04-30	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	04-26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	04-09	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	04-08	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	04-03	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	04-01	MT
Mereo BioPharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	03-25	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading	03-22	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	03-21	MT
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)	14/10/23	CI
Mereo BioPharma Group plc Reports Earnings Results for the Half Year Ended June 30, 2023	07/09/23	CI
Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study	05/06/23	CI
Mereo BioPharma Group plc Presents Phase 2 Data from â€œASTRAEUSâ€ Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference	23/05/23	CI
Mereo BioPharma Gets Approval for Listing Transfer to Nasdaq Capital Market	05/05/23	MT
Mereo BioPharma 2022 Net Loss Widens but Beats Expectations; Share Rise in Late Trade	28/03/23	MT
Mereo BioPharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2022	28/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mereo BioPharma Group plc

Equities

MREO

US5894921072

Highlights

Filters